Viatris (VTRS)

Viatris (VTRS-Q) has received mixed reviews from experts. One analyst appreciates the company's potential but emphasizes the need for a stronger focus on shareholder value. They note that the company is trading at a low price-to-earnings ratio of 7-8 times, indicating a possible opportunity for value investors. Another expert highlights that Viatris was spun out of Pfizer and has a limited market presence, describing it as a small-cap stock with a small footprint. This expert suggests that in the healthcare sector, only companies that are undervalued should be considered for investment. Overall, the sentiment suggests that while there are positives, caution is advised, particularly regarding growth prospects and market position.